OTC Markets OTCPK - Delayed Quote USD

Sartorius Stedim Biotech S.A. (SDMHF)

223.32
0.00
(0.00%)
At close: May 23 at 4:00:00 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Rene Faber CEO & DIrector 613.82k -- 1975
Ms. Petra Muller Head of Investor Relations -- -- --
Ms. Petra Kirchhoff Head of Corporate Communications & IR -- -- 1969

Sartorius Stedim Biotech S.A.

Zone Industrielle Les Paluds
Avenue de Jouques – CS 91051 Cedex
Aubagne, 13781
France
33 4 42 84 56 00 https://www.sartorius.com
Sector: 
Healthcare
Full Time Employees: 
9,961

Description

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides fluid management services; biolayer interferometry instruments; microbiology testing, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; screening instruments; biomolecule analysis tools; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; water purification systems; and weighing products. In addition, the company offers data analytics software; process automation platform and software; and transfection reagents and plasmid DNA solutions. It serves manufacturers of medications, vaccines, food, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.

Corporate Governance

Sartorius Stedim Biotech S.A.’s ISS Governance QualityScore as of May 1, 2025 is 6. The pillar scores are Audit: 3; Board: 4; Shareholder Rights: 8; Compensation: 7.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

July 22, 2025 at 5:00 AM UTC

Sartorius Stedim Biotech S.A. Earnings Date

Recent Events

April 2, 2025 at 12:00 AM UTC

Ex-Dividend Date

Related Tickers